These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1232 related articles for article (PubMed ID: 18606983)

  • 21. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
    Advani A; Coiffier B; Czuczman MS; Dreyling M; Foran J; Gine E; Gisselbrecht C; Ketterer N; Nasta S; Rohatiner A; Schmidt-Wolf IG; Schuler M; Sierra J; Smith MR; Verhoef G; Winter JN; Boni J; Vandendries E; Shapiro M; Fayad L
    J Clin Oncol; 2010 Apr; 28(12):2085-93. PubMed ID: 20308665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
    Goy A; Younes A; McLaughlin P; Pro B; Romaguera JE; Hagemeister F; Fayad L; Dang NH; Samaniego F; Wang M; Broglio K; Samuels B; Gilles F; Sarris AH; Hart S; Trehu E; Schenkein D; Cabanillas F; Rodriguez AM
    J Clin Oncol; 2005 Feb; 23(4):667-75. PubMed ID: 15613697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.
    Witzig TE; Vose JM; Zinzani PL; Reeder CB; Buckstein R; Polikoff JA; Bouabdallah R; Haioun C; Tilly H; Guo P; Pietronigro D; Ervin-Haynes AL; Czuczman MS
    Ann Oncol; 2011 Jul; 22(7):1622-1627. PubMed ID: 21228334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
    Vose JM; Habermann TM; Czuczman MS; Zinzani PL; Reeder CB; Tuscano JM; Lossos IS; Li J; Pietronigro D; Witzig TE
    Br J Haematol; 2013 Sep; 162(5):639-47. PubMed ID: 23834234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).
    Crump M; Baetz T; Couban S; Belch A; Marcellus D; Howson-Jan K; Imrie K; Myers R; Adams G; Ding K; Paul N; Shepherd L; Iglesias J; Meyer R
    Cancer; 2004 Oct; 101(8):1835-42. PubMed ID: 15386331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.
    Smith SM; Grinblatt D; Johnson JL; Niedzwiecki D; Rizzieri D; Bartlett NL; Cheson BD;
    Br J Haematol; 2008 Feb; 140(3):313-9. PubMed ID: 18217897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma.
    Sym SJ; Lee DH; Kang HJ; Nam SH; Kim HY; Kim SJ; Eom HS; Kim WS; Suh C
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):27-33. PubMed ID: 18839172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
    Leonard JP; Coleman M; Ketas J; Ashe M; Fiore JM; Furman RR; Niesvizky R; Shore T; Chadburn A; Horne H; Kovacs J; Ding CL; Wegener WA; Horak ID; Goldenberg DM
    J Clin Oncol; 2005 Aug; 23(22):5044-51. PubMed ID: 15955901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
    Fisher RI; Bernstein SH; Kahl BS; Djulbegovic B; Robertson MJ; de Vos S; Epner E; Krishnan A; Leonard JP; Lonial S; Stadtmauer EA; O'Connor OA; Shi H; Boral AL; Goy A
    J Clin Oncol; 2006 Oct; 24(30):4867-74. PubMed ID: 17001068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
    Morschhauser F; Fitoussi O; Haioun C; Thieblemont C; Quach H; Delarue R; Glaisner S; Gabarre J; Bosly A; Lister J; Li J; Coiffier B
    Eur J Cancer; 2013 Sep; 49(13):2869-76. PubMed ID: 23731832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma.
    Oki Y; McLaughlin P; Pro B; Hagemeister FB; Bleyer A; Loyer E; Younes A
    Cancer; 2005 Aug; 104(4):781-7. PubMed ID: 15973667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of concomitant chemoradiotherapy in bulky refractory or chemoresistant relapsed lymphomas.
    Girinsky T; Lapusan S; Ribrag V; Koscielny S; Ferme C; Carde P
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):476-9. PubMed ID: 15667970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
    Hess G; Smith SM; Berkenblit A; Coiffier B
    Semin Oncol; 2009 Dec; 36 Suppl 3():S37-45. PubMed ID: 19963099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
    Witzig TE; Geyer SM; Ghobrial I; Inwards DJ; Fonseca R; Kurtin P; Ansell SM; Luyun R; Flynn PJ; Morton RF; Dakhil SR; Gross H; Kaufmann SH
    J Clin Oncol; 2005 Aug; 23(23):5347-56. PubMed ID: 15983389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.
    Nowakowski GS; LaPlant B; Habermann TM; Rivera CE; Macon WR; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Klebig RR; Reeder CB; Witzig TE
    Leukemia; 2011 Dec; 25(12):1877-81. PubMed ID: 21720383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.
    Rizzieri DA; Sand GJ; McGaughey D; Moore JO; DeCastro C; Chao NJ; Vredenburgh JJ; Gasparetto C; Long GD; Anderson E; Foster T; Toaso B; Adams D; Niedzwiecki D; Gockerman JP
    Cancer; 2004 Jun; 100(11):2408-14. PubMed ID: 15160345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.
    Younes A; Sureda A; Ben-Yehuda D; Zinzani PL; Ong TC; Prince HM; Harrison SJ; Kirschbaum M; Johnston P; Gallagher J; Le Corre C; Shen A; Engert A
    J Clin Oncol; 2012 Jun; 30(18):2197-203. PubMed ID: 22547596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.
    Hernandez-Ilizaliturri FJ; Deeb G; Zinzani PL; Pileri SA; Malik F; Macon WR; Goy A; Witzig TE; Czuczman MS
    Cancer; 2011 Nov; 117(22):5058-66. PubMed ID: 21495023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
    Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
    Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
    Rummel MJ; Al-Batran SE; Kim SZ; Welslau M; Hecker R; Kofahl-Krause D; Josten KM; Dürk H; Rost A; Neise M; von Grünhagen U; Chow KU; Hansmann ML; Hoelzer D; Mitrou PS
    J Clin Oncol; 2005 May; 23(15):3383-9. PubMed ID: 15908650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.